Opinion

Video

Clinical Pearls & Unmet Needs in Early and Late Relapse R/R MM

Author(s):

Robert Z. Orlowski, MD, PhD,Jonathan L. Kaufman, MD

The relapsed/refractory multiple myeloma experts conclude by highlighting current unmet needs in the field and sharing valuable clinical pearls to guide practice and improve patient outcomes.

Related Videos
Mansi R. Shah, MD
3 experts are featured in this series.
2 experts in this video
2 experts in this video
Amer Zeidan, MBBS, and Guillermo Garcia-Manero, MD, discuss current treatment trends in myelodysplastic syndromes.
Stephanie Graff, MD, and Chandler Park, FACP
2 experts in this video
2 experts in this video
Related Content
Michael Wang, MD
December 18th 2024

Long-Term Data Support Continued Use of Brexu-Cel in R/R Mantle Cell Lymphoma

Jaffer A. Ajani, MD, GI medical oncologist, professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
November 14th 2024

FDA Approval Insights: Zolbetuximab for CLDN18.2+ HER2-Negative Gastric and GEJ Adenocarcinoma

Smoldering Myeloma
December 11th 2024

Cilta-Cel Leads to 100% MRD-Negativity Rate in High-Risk Smoldering Multiple Myeloma

Guillermo Garcia-Manero, MD, professor, chief, section of Myelodysplastic Syndromes, deputy chair, Translational Research, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
August 19th 2024

Garcia-Manero on MDS Treatment Updates With Luspatercept and Beyond

Reshma Jagsi, MD, DPhil, of Winship Cancer Institute
December 11th 2024

Lancet Breast Cancer Commission Report Addresses Challenges to Reduce Disease Burden

ASH Annual Meeting | Image Credit: ©alionaprof – stock.adobe.com
December 10th 2024

Isa-RVd Induction Provides Significant PFS Benefit in Newly Diagnosed Multiple Myeloma